{"id":"W4281645619","doi":"10.1056/evidoa2100070","title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","year":2022,"lang":"en","type":"article","venue":"NEJM Evidence","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1432,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Internal medicine; Confidence interval; Oncology; Regimen; Urology; Surgery; Cancer; Immunotherapy; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001263914,0.0003041235,0.001225562,0.0002158508,0.000155457,0.0002622326,0.000271846,0.0001942789,0.00131479],"category_scores_gemma":[0.001012631,0.0001559154,0.0004921911,0.0002836569,0.0003199205,0.0002922216,0.000291497,0.0006221075,0.0002347259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006561092,"about_ca_system_score_gemma":0.0007254682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004687779,"about_ca_topic_score_gemma":0.001260701,"domain_scores_codex":[0.999663,0.0001635915,0.00003842696,0.00004739614,0.00005178576,0.0000357988],"domain_scores_gemma":[0.9994687,0.0002017223,0.0001017236,0.00002817639,0.00002220049,0.0001774992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5633786,0.007266184,0.07525606,0.002189457,0.002296265,0.0008815714,0.0002675578,0.005770899,0.02754927,0.0004252975,0.001885405,0.3128334],"study_design_scores_gemma":[0.2766361,0.5098261,0.1750364,0.0002526684,0.002725625,0.003350895,0.0002680834,0.008788622,0.01340661,0.0008562413,0.008791929,0.00006073267],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996488,0.00256159,0.0001677182,0.0001103248,0.00002714531,0.0001224974,0.00007317515,0.000009075802,0.0004404506],"genre_scores_gemma":[0.9981478,0.001114579,0.000207152,0.0000815451,0.00002802153,0.0001010206,0.0001678509,0.000002114782,0.0001499432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00131479,"threshold_uncertainty_score":0.006684303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1253603055975009,"score_gpt":0.2842659688337804,"score_spread":0.1589056632362795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}